Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05624528 · ClinicalTrials.gov registry record · Phase 2
A Clinical Trial of Tolcapone in Obsessive Compulsive Disorder
A Phase 2 study of Obsessive - Compulsive Disorder and OCD, sponsored by University of Chicago.
- Active
- Registry status
- Phase 2
- Development phase
- 49
- Enrollment target
- 1
- Study location
NCT05624528 is a Phase 2 study of Obsessive - Compulsive Disorder and OCD that is active but no longer recruiting, run by University of Chicago. The registered enrollment target is 49 participants, below the 2,064-participant average among 84 other Obsessive - Compulsive Disorder trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05624528, a Phase 2 study of Obsessive - Compulsive Disorder and OCD, is active but no longer recruiting, sponsored by University of Chicago.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 49 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary aim of the present study is to examine the efficacy and safety of tolcapone in adults with moderate to severe OCD.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tolcapone
Study Locations (1)
Illinois
- University of Chicago Medical Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2023-06-22 |
| Est. Completion | 2026-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05624528
The ClinicalTrials.gov registry entry for NCT05624528 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,064-participant average among 84 other Obsessive - Compulsive Disorder trials with a reported enrollment target (98% lower). The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Obsessive - Compulsive Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05624528 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT05624528 about?
NCT05624528 is a clinical study titled "A Clinical Trial of Tolcapone in Obsessive Compulsive Disorder". The primary aim of the present study is to examine the efficacy and safety of tolcapone in adults with moderate to severe OCD.
What is the current status of trial NCT05624528?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 49 participants. The study started on 2023-06-22. Estimated completion is 2026-06.
What conditions does trial NCT05624528 study?
This clinical trial studies the following conditions: Obsessive - Compulsive Disorder, OCD.
What interventions are being tested in trial NCT05624528?
The interventions under investigation include: Placebo (DRUG), Tolcapone (DRUG).
Who is sponsoring clinical trial NCT05624528?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05624528 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obsessive - Compulsive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
MDMA-Assisted CBT for OCD (MDMA-CBT4OCD Study)
RECRUITING · Phase 2
-
Efficacy of Nitrous Oxide in OCD: Pilot Study
RECRUITING · Phase 2
-
Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness
RECRUITING · Phase 2
-
Examining Mu Opioid Mechanisms of Ketamine's Rapid Effects in OCD (MKET2)
RECRUITING · Phase 2
-
Study of Dextromethorphan in OCD and Related Disorders
RECRUITING · Phase 2
-
Understanding How Ketamine Brings About Rapid Improvement in OCD
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.